Skip to main content

ACP: Recommendations Developed for Newer Type 2 Diabetes Medications

Medically reviewed by Carmen Pope, BPharm. Last updated on April 22, 2024.

By Elana Gotkine HealthDay Reporter

MONDAY, April 22, 2024 -- In a clinical guideline issued by the American College of Physicians (ACP) and published online April 19 in the Annals of Internal Medicine, recommendations are presented regarding newer pharmacologic treatments for adults with type 2 diabetes. Details of the guideline were also presented at the Internal Medicine Meeting, the annual meeting of ACP, held from April 18 to 20 in Boston.

Amir Qaseem, M.D., Ph.D., from ACP in Philadelphia, and colleagues developed clinical guidelines based on the best available evidence for effectiveness, comparative benefits and harms, consideration of patients' values and preferences, and costs for type 2 diabetes treatments. The effectiveness and harms of newer pharmacologic treatments, including glucagon-like peptide-1 (GLP-1) agonists, a GLP-1 agonist and glucose-dependent insulinotropic polypeptide agonist, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, and long-acting insulins were reviewed.

For adults with type 2 diabetes and inadequate glycemic control, the authors recommend the addition of an SGLT-2 inhibitor or GLP-1 agonist to metformin and lifestyle modifications (strong recommendation). An SGLT-2 inhibitor can reduce the risk for all-cause mortality, major adverse cardiovascular events, chronic kidney disease progression, and hospitalization due to congestive heart failure. Use of a GLP-1 agonist can reduce the risk for all-cause mortality, major adverse cardiovascular events, and stroke. To reduce morbidity and all-cause mortality, the addition of a DPP-4 inhibitor to metformin and lifestyle modification is not recommended for adults with type 2 diabetes and inadequate glycemic control (strong recommendation).

"ACP continues to recommend starting treatment with metformin and adding other agents only when glycemic goals are not met or comorbid conditions warrant their use," Fatima Z. Syed, M.D., from Duke University in Durham, North Carolina, writes in an accompanying editorial.

Abstract/Full Text

Editorial (subscription or payment may be required)

Review 1

Review 2

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

ACG: 2000 to 2022 Saw Rise in Early-Onset CRC Mortality in the United States

THURSDAY, Oct. 31, 2024 -- Early-onset colorectal cancer (EO-CRC) mortality rose in the United States over the past two decades, most notably in patients aged 20 to 44 years...

Cell-Free Blood DNA Tests Less Effective Than Other CRC Screening

WEDNESDAY, Oct. 30, 2024 -- Cell-free DNA blood tests (cf-bDNA) may be more costly and less effective for colorectal cancer (CRC) screening than other screening modalities...

Small but Important Differences Seen Between Rosuvastatin, Atorvastatin

WEDNESDAY, Oct. 30, 2024 -- There are small but important differences in risk for some clinical outcomes associated with rosuvastatin and atorvastatin, according to a study...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.